Preclinical work ties innate immune signaling to pancreatic cancer progression via TREM1-driven neutrophil extracellular trap formation, proposing a prognostic biomarker and therapeutic target. Separately, a review proposes a RUNX2–TGF-beta feedback loop model that could explain chemotherapy resistance in triple-negative breast cancer, offering a framework for future mechanistic and therapeutic testing.